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REPLY
The writing group of the “Scientific Statement on the Evaluation
of Syncope” takes this opportunity to respond to the critique of this
document (1) by Dr. Benditt and colleagues. The goal of this
Scientific Statement, as set forth by the sponsoring organizations,
was to provide a concise, practical approach to the initial evaluation
of the patient with syncope within strict length limitations (2). The
document approaches the evaluation of syncope as a clinician
would when a patient presents to the office or hospital with such an
event. The emphasis of this document is placed on the recognition
of life-threatening clinical syndromes.
The criticisms of Dr. Benditt and colleagues can be grouped
into three categories. First, the definition of syncope was inade-
quate. Second, the stated goal of preventing death is not adequate,
and the goal for the evaluation of syncope should also be to
establish a diagnosis and provide a prognosis. Third, the citations
were incomplete.
The definition of syncope as “a transient loss of consciousness”
fits into the category of a practical working definition. Although
there is no uniform consensus on the ideal definition, the defini-
tion often includes reference to the loss of consciousness due to
global cerebral hypoperfusion. Unfortunately, this definition can
be strictly applied only when the mechanism of syncope is firmly
established. The definition used in this document relates to the
clinical presentation, as commonly used and understood, and does
not require a specific mechanistic diagnosis. Academically, one
might prefer a more detailed or thorough definition. However, one
could also argue that any definition intended to be used universally
should be developed by international consensus among appropriate
medical societies. To date, this has not been achieved.
The specific etiology of syncope is identified in only about
one-half of the patients who undergo an evaluation for syncope.
Furthermore, many patients never have a recurrence after an
episode of syncope, and only occasionally is syncope disabling.
Ultimately, one can have many goals for a document of this type.
We chose the identification of the patient at risk of death as the
primary one.
Dr. Benditt and colleagues correctly state that many references
relevant to syncope were not cited. Owing to space considerations
and the document’s focus on the evaluation of syncope, many
excellent papers could not be referenced. We agree that the
“Guidelines on Management (Diagnosis and Treatment) of Syn-
cope” developed by the European Society of Cardiology are
particularly important documents, and we apologize for omitting
them (3,4).
The “Scientific Statement on the Evaluation of Syncope” was
reviewed and evaluated by 50 outside reviewers. The document
was reviewed and approved by the American Heart Association
(AHA), American College of Cardiology Foundation, Heart
Rhythm Society, and the American Autonomic Society. Criticisms
and comments offered by these reviewers and organizations were
responded to and incorporated into the final document. Although
there are inherent limitations to any such document, the writing
group believes that the “Scientific Statement on the Evaluation of
Syncope” achieves the goals set forth by the AHA for this
document, and it provides a concise and practical approach to the
initial evaluation of syncope.
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Examining the Concept
of Preserved Systolic Function
Sophisticated analyses and the size of the Acute Decompensated
Heart Failure National Registry (ADHERE) database strengthen
the characterization of heart failure with preserved systolic func-
tion (PSF) made by Yancy et al. (1). Unfortunately, PSF includes
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